Solventum reported strong growth across its business segments and raised its sales growth guidance, indicating positive momentum. However, the company faces significant challenges from tariffs that will impact profitability in the second half of the year.

Company Guidance -

Q2 2025

In the first quarter of fiscal year 2025, Solventum demonstrated robust financial performance, prompting an increase in their organic revenue guidance to 1.5% to 2.5% for the year. The company reported a 4.3% organic sales growth and adjusted earnings per share (EPS) of $1.34, marking their fourth consecutive quarter of positive growth. Despite facing headwinds from tariffs, Solventum maintained its EPS guidance between $5.45 and $5.65 by leveraging favorable foreign exchange rates and implementing mitigation strategies. The MedSurg segment led with a 6% organic growth, driven by improved commercial execution and successful product launches. The Dental Solutions segment showed resilience with a 0.4% growth amidst market challenges. Solventum's focus remains on executing its transformation plan, enhancing commercial productivity, and investing in growth areas to deliver sustainable improvement and shareholder value.

Strong Start to 2025

Solventum began fiscal year 2025 with a strong performance, showcasing 4.3% organic sales growth and adjusted earnings per share of $1.34, marking four consecutive quarters of positive growth.

MedSurg Segment Performance

The MedSurg business reported a very strong quarter, achieving 6% organic growth driven by positive business performance and favorable order timing.

Dental Solutions and New Product Launches

The Dental Solutions segment showed resilience with new product launches like Filtek Easy Match and Clarity Precision Grip Attachments, aiding in offsetting market challenges.

Health Information Systems Growth

The HIS segment saw a 3.9% increase in revenue, driven by strong customer retention in Revenue Cycle Management software solutions.

Purification & Filtration Segment Demand

The Purification & Filtration segment experienced robust demand for bioprocessing solutions, indicating strength in end markets.

Guidance Adjustment

Solventum raised its full-year organic sales growth guidance to 1.5% to 2.5%, reflecting strong business momentum.

Solventum Corporation (SOLV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SOLV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	1.45 / -	1.56	―	―	―
May 08, 2025	2025 (Q1)	1.21 / 1.34	2.08	-35.58% (-0.74)
Feb 27, 2025	2024 (Q4)	1.31 / 1.41	2.311	-38.99% (-0.90)
Nov 07, 2024	2024 (Q3)	1.39 / 1.64	2.664	-38.44% (-1.02)
Aug 08, 2024	2024 (Q2)	1.50 / 1.56	1.859	-16.08% (-0.30)	―
May 09, 2024	2024 (Q1)	1.75 / 2.08	1.696	22.64% (+0.38)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SOLV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$66.63	$70.23	+5.40%
Feb 27, 2025	$83.44	$79.75	-4.42%
Nov 07, 2024	$75.07	$72.43	-3.52%
Aug 08, 2024	$58.66	$60.59	+3.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.